Concepedia

Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial

Torben Kjær Nielsen, Martin Højgaard, Jón Trærup Andersen, Niklas Rye Jørgensen, Bo Zerahn, Bent Bruun Kristensen, Trine Henriksen

Translational Andrology and Urology · 2017 · 51 citations · 39 references

DOIFull text

Open access

Abstract

Infusion with 60 g of AA did not result in disease remission. This study does not support the use of intravenous AA outside clinical trials.

References

39

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 15.4K citations

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.4K citations

, , +14

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.4K citations · Full text

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text